Trials / Withdrawn
WithdrawnNCT03580005
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release Chewable Tablets (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 4 Years – 5 Years
- Healthy volunteers
- Not accepted
Summary
A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | methylphenidate HCl ERCT | methylphenidate HCl ERCT |
| DRUG | Placebo | Placebo to Match Quillichew ERCT |
Timeline
- Start date
- 2018-10-31
- Primary completion
- 2021-10-12
- Completion
- 2021-10-12
- First posted
- 2018-07-09
- Last updated
- 2018-11-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03580005. Inclusion in this directory is not an endorsement.